McKesson Corporation Earnings Recaps
Q2 2027
Nov 7, 2026
McKesson shares were roughly flat, up 0.3% after earnings. The quarter included higher revenue and EPS and a raised full-year EPS outlook, but the market reaction was muted.
Key takeaways
- Second-quarter revenue increased 8% year over year, with growth across all segments; adjusted EPS rose 18%.
- McKesson raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40, from $44.20–$45 previously.
- The company completed its acquisition of Precision Medicine Group, adding clinical research and biopharma market-access capabilities.
- McKesson also agreed to make a strategic investment in Option Care Health; the transaction remains subject to customary closing conditions, including stockholder and regulatory approvals.
- Management cited drug innovation and stable utilization as supportive trends in oncology and multispecialty, and highlighted the continued expansion of its retina and ophthalmology platform.
Q4 2026
May 8, 2026
McKesson shares declined modestly by 1.0% following its fiscal Q4 2026 report, reflecting investor caution amid a muted outlook for fiscal 2027 despite stable operational execution and ongoing strategic progress.
Key takeaways
- Adjusted earnings per diluted share grew 18% in fiscal 2026, supported by growth across strategic platforms.
- Operating cash flow reached $6.2 billion, surpassing internal plans, with $5.1 billion returned to shareholders.
- Continued progress on Medical-Surgical Solutions separation, including transition service agreements and minority investor partnership with Apollo.
- Fiscal 2027 EPS guidance range set at $43.80 to $44.60, lacking upward revision and suggesting limited near-term earnings acceleration.
- Strategic initiatives such as oncology platform expansion and technology adoption continue, though offset by restrained margin commentary and cautious outlook.
Q3 2026
Feb 5, 2026
McKesson Corporation delivered robust third-quarter results for fiscal 2026, showcasing double-digit revenue and earnings growth driven by continued strength in oncology, biopharma services, and North American distribution. The company raised its full-year EPS guidance, reflecting strong momentum across its strategic initiatives.
Key takeaways
- Revenue and adjusted EPS increased by 17-19% year-over-year, indicating strong business momentum.
- Integration of acquired entities such as Florida Cancer Specialists and Prism Vision enhances McKesson's oncology services and market position.
- Introduction of 50 new programs across diverse brands demonstrates strong demand for patient access and affordability solutions.
- Continued investment in technology improves workflow efficiency, with employees now supporting 120 more patients per full-time staff in annual verification.
- Strong partnerships with manufacturers and advocacy efforts align with the evolving healthcare landscape and regulatory changes.